TGFBR2 KO CAR27/IL-15 NK cells / UT MD Anderson Cancer Center - LARVOL DELTA

TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=37 | Suspended | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Suspended

Trial suspension • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2026 ➔ May 2026

Enrollment open • Pan tumor • Trial initiation date • Hematological Malignancies • Lymphoma • Oncology • ABL1 • BCR

Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=37 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P1/2 trial • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Ovarian Cancer • Solid Tumor

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P1 trial • Pan tumor • Hematological Malignancies • Lymphoma • Oncology • ABL1 • BCR